J&J’s Consumer Woes Finally Subside As Pharma Continues Strong
This article was originally published in The Pink Sheet Daily
Executive Summary
The multinational health care company reported significant growth in 2013 that largely was driven by its pharmaceutical division, but bolstered by the resurrection of its long-plagued consumer brands.
You may also be interested in...
Emerging Markets Earnings Roundup: Johnson & Johnson, Abbott (Part 1)
Emerging markets received a lot of attention during the fourth quarter earnings calls of both Abbott Laboratories and J&J. CEOs at both companies proved upbeat on the year ahead and talked about momentum across product lines from medical devices to pharmaceuticals.
Emerging Markets Earnings Roundup: Johnson & Johnson, Abbott (Part 1)
Emerging markets received a lot of attention during the fourth quarter earnings calls of both Abbott Laboratories and J&J. CEOs at both companies proved upbeat on the year ahead and talked about momentum across product lines from medical devices to pharmaceuticals.
J&J’s Solid Launches Lead Strong Pharma Segment Quarter
Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.